Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Lisa Landrum

Chair

Indiana University School of Medicine

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Jeffrey F. Peipert

Professor & Chair

University of Vermont

UNITED STATES

View details

Giorgio Valabrega

University of Turin

ITALY

View details

Jesus Gonzalez Bosquet

Iowa State University

UNITED STATES

View details

Laurel Berry

Assistant Professor

Wake Forest Baptist Medical Center

UNITED STATES

View details

Debra Richardson

Professor and Section Chief

University of Kansas Cancer Center

UNITED STATES

View details

Toon Van Gorp

Professor

Universitaire Ziekenhuizen Leuven

BELGIUM

View details

Sakari Hietanen

Chief of Dept.

Helsinki University Hospital

FINLAND

View details

David Bender

The University of Iowa University College

UNITED STATES

View details

Kenneth P Nephew

Professor

Indiana University

UNITED STATES

View details

Emily Hill

University of Iowa Healthcare

UNITED STATES

View details

Zoltan Novak

Head of Department

National Institute of Oncology

HUNGARY

View details

Ahmad Tarhini

Senior Member, Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES

View details

Joe R Delaney

Associate Professor

Medical University of South Carolina

UNITED STATES

View details

Thomas Herzog

Professor

University of Cincinnati

UNITED STATES

View details

Casey Cosgrove

Ohio State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lisa Landrum

Research Interests

Make your next move.

Explore related searches

Articles (20)

Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel.

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer

Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer – An NRG/GOG study

Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".

Sertoli-Leydig cell tumor with <i>DICER1</i> mutation.

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.

Collaborators (15)

Jeffrey F. Peipert

Giorgio Valabrega

Jesus Gonzalez Bosquet

Laurel Berry

Debra Richardson

Toon Van Gorp

Sakari Hietanen

David Bender

Kenneth P Nephew

Emily Hill

Zoltan Novak

Ahmad Tarhini

Joe R Delaney

Thomas Herzog

Casey Cosgrove

Make your next move.